Please assess the completion status of the following clinical trial:

Trial Title: Coagulation and Fibrinolysis of Estradiol in Transwomen

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Gender identity of male to female or transwoman~Exclusion Criteria:~* Liver disease~* History of blood clot~* Bleeding disorder~* Active or recent (e.g., within the past year) stroke~* Myocardial infarction,~* History of orchiectomy~* History of breast cancer,~* Known sensitivity or allergy to any components of the medications used~* Currently taking a potent CYP3A4 inhibitor or inducer.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sublingual Estradiol (Type: ACTIVE_COMPARATOR): Sublingual estradiol administered for 8 weeks
- Oral Estradiol (Type: ACTIVE_COMPARATOR): Oral estradiol administered for 8 weeks
- Transdermal Estradiol (Type: ACTIVE_COMPARATOR): Transdermal estradiol administered for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).